Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
ETF Daily News8d
Contrasting Pharmaxis (OTCMKTS:PXSLY) & iBio (NYSE:IBIO)
The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting ...
Stockhead on MSN2d
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
VIVUS’ QSYMIA® to be Featured on Health Uncensored with Dr. Drew
John Amos, Dr. Farhad Zangeneh, Medical Director of Endocrine, Diabetes and Osteoporosis Clinic, Dr. Dina Peralta-Reich, New York Weight Wellness Medicine Founder and Director, and Peter Maher, a ...
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this ...
Medscape5d
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
Sumatriptan and others are contraindicated in patients taking monoamine oxidase (MAO ... headaches), isometheptene (a sympathomimetic amine with vasoconstriction properties) and dichloralphenazone ...